Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3175-3182

  Lau, Kin Mang ^b,c   LaSpina, Mark ^a,c   Long, John ^d   Ho, Shuk Mei ^b  

^a New England College of Osteopathy   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; GENE SILENCING; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL CULTURE TECHNIQUES; CELL DIVISION; CELLS, CULTURED; DIETHYLSTILBESTROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS, NON-STEROIDAL; HUMANS; MALE; METHYLATION; OLIGONUCLEOTIDES, ANTISENSE; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0034126666     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Huggins, C., and Hodges, C. V. Studies of prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
2. Paulson, D. F. Management of metastatic prostatic cancer. Urology, 25 (2 Suppl.): 49-52, 1985.
3. Brehmer, B., Marquardt, H., and Madsen, P. O. Growth and hormonal response of cells derived from carcinoma and hyperplasia of the prostate in monolayer cell culture. A possible in vitro model for clinical chemotherapy. J. Urol., 108: 890-896, 1972.
4. Hartley-Asp, B., Deinum, J., and Wallin, M. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly. Mutat. Res., 143: 231-235, 1985.
5. Schulze, H., and Claus, S. Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate, 16: 331-343, 1990.
6. Robertson, C. N., Roberson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C. S., and Fine, R. L. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst., 88: 908-917, 1996.
7. Ahmed, M., Choksy, S., Chilton, C. P., Munson, K. W., and Williams, J. H. High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate. Int. Urol. Nephrol., 30: 159-164, 1998.
8. Glick, J. H., Wein, A., Padavic, K., Negendank, W., Harris, D., and Brodovsky, H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer (Phila.), 49: 1367-1372, 1982.
9. Spremulli, E., DeSimone, P., and Durant, J. A phase II study of Nolvadex® tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am. J. Clin. Oncol., 5: 149-153, 1982.
10. Horton, J., Rosenbaum, C., and Cummings, F. J. Tamoxifen in advanced prostate cancer: an ECOG pilot study. Prostate, 12: 173-177, 1988.
11. Bergan, R. C., Blagosklonny, M., and Dawson, N. A. Significant activity by high dose tamoxifen in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol., 14: A637, 1995.
12. Bergan, R. C., Reed, E., Myers, C. E., Headlee, D., Brwley, O., Cho, H-K., Figg, W. D., Tompkins, A., Linehan, W. M., Kohler, D., Steinber, S. M., and Blagosklonny, M. V. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin. Cancer Res., 5: 2366-2373, 1999.
13. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
14. Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl) benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem., 27: 1057-1066, 1984.
15. Van Den Bemd, G. J., Kuiper, G. G., Pols, H. A., and Van Leeuwen, J. P. Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164,384 and ICI 182-780 leading to opposite effects on receptor stability. Biochem. Biophys. Res. Commun., 261: 1-5, 1999.
16. Zou, A., Marschke, K. B., Arnold, K. E., Berger, E. M., Fitzgerald, P., Mais, D. E., and Allegretto, E. A. Estrogen receptor β activates the human retinoic acid receptor α-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol., 13: 418-430, 1999.
17. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J., and Nilsson, S. Differential response of estrogen receptor alpha and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol., 54: 105-112, 1998.
18. Paech, K., Webb, P., Kuiper, G. G., Nilsson, S., Gustafsson, J., Kushner, P. J., and Scanlan, T. S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science (Washington DC), 277: 1508-1510, 1997.
19. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925-5930, 1997.
20. Mosselman, S., Polman, J., and Dijkema, R. ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53, 1996.
21. Lau, K. M., Leav, I., and Ho, S. M. Rat estrogen receptor-α and -β, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology, 139: 424-427, 1997.
22. Prins, G. S., Marmer, M., Woodham, C., Chang, W., Kuiper, G., Gustafsson, J. A., and Birch, L. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology, 139: 874-883, 1998.
23. Chang, W. Y., and Prins, G. S. Estrogen receptor-β: implications for the prostate gland. Prostate, 40: 115-124, 1999.
24. Montano, M. M., Jaiswal, A. K., and Katzenellenbogen, B. S. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-α and estrogen receptor-β. J. Biol. Chem., 273: 25443-25449, 1998.
25. Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J. A., and Smithies, O. Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc. Natl. Acad. Sci. USA, 95: 15677-15682, 1998.
26. Bonkhoff, H., Fixemer, T., Hunsicker, I., and Remberger, K. Estrogen receptor expression in prostate cancer and malignant prostatic lesions. Am. J. Pathol., 155: 641-647, 1999.
27. Lau, K. M., LaSpina, M., Long, J., and Ho, S-M. Antiestrogens, via ERβ pathway, inhibit growth of prostate cancer cells. Proc. Am. Assoc. Cancer Res., 40: 637-638, 1999.
28. Sinisi, A., Pasquali, D., Rossi, V., Abbondanza, C., Puca, G. A., and Bellastella, A. Different expression of estrogen receptor α and β in primary cultures of normal and malignant human prostate epithelial cells. Proc. Endocr. Soc. 81th Annual Meeting, Vol. PAB99, p. 264, 1999.
29. Taylor, A. H., Davis, I., and Al-Azzawi, F. Immunolocalisation of estrogen receptor isoform ERβ in formalin-fixed paraffin-embedded normal human reproductive tissues. Proc. Endocr. Soc. 81th Annual Meeting, Vol. PAB99, p. 183, 1999.
30. Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N., and Narayan, P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev. Biol. Anim., 31: 14-24, 1995.
31. Bright, R. K., Vocke, C. D., Emmert-Buck, M. R., Duray, P. H., Solomon, D., Fetsch, P., Rhim, J. S., Linehan, W. M., and Topalian, S. L. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res., 57: 995-1002, 1997.
32. Lau, K. M., Mok, S. C., and Ho, S. M. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl. Acad. Sci. USA, 96: 5722-5727, 1999.
33. Grant, E. S., Batchelor, K. W., and Habib, F. K. Androgen independence of primary epithelial cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate, 29: 339-349, 1996.
34. Sugimura, Y., Cunha, G. R., Yonemura, C. U., and Kawamura, J. Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia of the developing human prostate. Hum. Pathol., 19: 133-139, 1988.
35. Yonemura, C. Y., Cunha, G. R., Sugimura, Y., and Mee, S. L. Temporal and spatial factors in diethylstilbestrol-induced squamous metaplasia in the developing human prostate. II. Persistent changes after removal of diethylstilbestrol. Acta Anat., 153: 1-11, 1995.
36. Triche, T. J., and Harkin, J. C. An ultrastructural study of hormonally induced squamous metaplasia in the coagulating gland of the mouse prostate. Lab. Investig., 25: 596-606, 1971.
37. Levine, A. C., Kirschenbaum, A., Droller, M., and Gabrilove, J. L. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy. J. Urol., 146: 790-793, 1991.
38. Noble, R. L. Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res., 40: 3547-3550, 1980.
39. Drago, J. R. The induction of NB rat prostatic carcinomas. Anticancer Res., 4: 255-256, 1984.
40. Leav, I., Merk, F. B., Kwan, P. W., and Ho, S. M. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate, 15: 23-40, 1995.
41. Bosland, M. C., Ford, H., and Horton, L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17β or diethylstilbestrol. Carcinogenesis (Lond.), 16: 1311-1317, 1995.
42. Klotz, L., McNeill, I., and Fleshner, N. A Phase 1-2 trial of diethylstilbestrol plus low-dose warfarin in advanced prostate carcinoma. J. Urol., 161: 169-172, 1999.
43. Smith, D. C., Redman, B. G., Flaherty, L. E., Li, L., Strawderman, M., and Pienta, K. J. A Phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology, 52: 257-260, 1998.
44. Landstrom, M., Eklov, S., Colosetti, P., Nilsson, S., Damber, J. E., Bergh, A., and Funa, K. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-β1 and its type-I and type-II receptors. Int. J. Cancer, 67: 573-579, 1996.
45. Wernert, N., Gerdes, J., Loy, V., Seitz, G., Scherr, O., and Dhom, G. Investigations of the estrogen (ER-ICA-test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch. A Pathol. Anat. Histopathol., 412: 387-391, 1988.
46. Ehara, H., Koji, T., Deguchi, T., Yoshii, A., Nakano, M., Nakane, P. K., and Kawada, Y. Expression of estrogen receptor in diseased human prostate assessed by non-radioactive in situ hybridization and immunohistochemistry. Prostate, 27: 304-313, 1995.
47. Kirschenbaum, A., Ren, M., Erenburg, I., Schachter, B., and Levine, A. C. Estrogen receptor messenger RNA expression in human benign prostatic hyperplasia: detection, localization, and modulation with a long-acting gonadotropin-releasing hormone agonist. J. Androl., 15: 528-533, 1994.
48. Hiramatsu, M., Maehara, I., Orikasa, S., and Sasano, H. Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma. Histopathology, 28: 163-168, 1996.
49. Rohlff, C., Blagosklonny, M. V., Kyle, E., Kesari, A., Kim, I. Y., Zelner, D. J., Hakim, F., Trepel, J., and Bergan, R. C. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21 (waf1/cip1). Prostate, 37: 51-59, 1998.
50. Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J. A., and Korach, K. S. Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology, 138: 4613-4621, 1997.
51. Carruba, G., Pfeffer, U., Fecarotta, E., Coviello, D. A., D'Amoto, E., Lo Castro, M., Vidali, G., and Castagnetta, L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res., 54: 1190-1193, 1994.
52. Castagnetta, L. A., Miceli, M. D., Sorci, C. M., Pfeffer, U., Farruggio, R., Oliveri, G., Calabro, M., and Carruba, G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology, 136: 2309-2319, 1995.
53. Hobisch, A., Hittmair, A., Daxenbichler, G., Wille, S., Radmayr, C., Hobisch-Hagen, P., Bartsch, G., Klocker, H., and Culig, Z. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J. Pathol., 182: 356-361, 1998.
54. Konishi, N., Nakaoka, S., Hiasa, Y., Kitahori, Y., Ohshima, M., Samma, S., and Okajima, E. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. Oncology, 50: 259-263, 1993.
55. Castagnetta, L. A., and Carruba, G. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J. Pathol., 185: 435-437, 1998.
56. Brown, A. M., Jeltsch, J. M., Roberts, M., and Chambon, P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. USA, 81: 6344-6348, 1984.
57. Stack, G., Kumar, V., Green, S., Ponglikitmongkol, M., Berry, M., Rio, M. C., Nunez, A. M., Roberts, M., Koehl, C., Bellocq, P., et al. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treat. Res., 40: 185-206, 1988.
58. Savouret, J. F., Bailly, A., Misrahi, M., Rauch, C., Redeuilh, G., Chauchereau, A., and Milgrom, E. Characterization of the hormone responsive element involved in the regulation of the progesterone receptor gene. EMBO J., 10: 1875-1883, 1991.
59. Zingg, J. M., and Jones, P. A. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis (Lond.), 18: 869-882, 1997.
60. Jones, P. A., and Gonzalgo, M. L. Altered DNA methylation and genome instability: a new pathway to cancer? Proc. Natl. Acad. Sci. USA, 94: 2103-2105, 1997.
61. Ottaviano, Y. L., Issa, J. P., Parl, F. F., Smith, H. S., Baylin, S. B., and Davidson, N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res., 54: 2552-2555, 1994.
62. Ferguson, A. T., Lapidus, R. G., Baylin, S. B., and Davidson, N. E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res., 55: 2279-2283, 1995.
63. Martin, V., Ribieras, S., Song-Wang, X., Rio, M. C., and Dante, R. Genomic sequencing indicates a correlation between DNA hypomethylation in the 5′ region of the pS2 gene and its expression in human breast cancer cell lines. Gene (Amst.), 157: 261-264, 1995.
64. Lapidus, R. G., Nass, S. J., Butash, K. A., Parl, F. F., Weitzman, S. A., Graff, J. G., Herman, J. G., and Davidson, N. E. Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res., 58: 2515-2519, 1998.
65. Bonkhoff, H., Stein, U., Welter, C., and Remberger, K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum. Pathol., 26: 824-828, 1995.
66. Colombel, M., Dantem, R., Bouvier, R., Ribieras, S., Pangaud, C., Marechal, M., and Lasne, Y. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue. J. Urol., 162 (3 Part 1): 927-930, 1999.
67. Hirata, S., Yamada-Mouri, N., Nara, M., Takizawa, M., Ito, H., and Kato, J. Presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. Endocr. J., 42: 289-293, 1995.
68. Leygue, E. R., Watson, P. H., and Murphy, L. C. Estrogen receptor variants in normal human mammary tissue. J. Natl. Cancer Inst., 88: 284-290, 1996.
69. Chaudoreille, M. M., Peyrot, V., Braguer, D., and Crevat, A. Interaction of some estrogenic drugs with tubulin. Formation of twisted ribbon structures. Mol. Pharmacol., 32: 731-736, 1987.
70. Robertson, C. N., Robertson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C. S., Fine, R. L. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J. Natl. Cancer Inst., 88: 908-917, 1996.
71. Reynolds, T. New estrogen receptor adds complexity, recasts drug strategies. J. Natl. Cancer Inst., 91: 1445-1447, 1999.
72. England, G. M., and Jordan, V. C. Pure antiestrogens as a new therapy for breast cancer. Oncol. Res., 9: 397-402, 1997.
73. Montano, M. M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., and Katzenellenbogen, B. S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens Proc. Natl. Acad. Sci. USA, 96: 6947-6952, 1999.